BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18262085)

  • 1. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.
    D'Ambrosio DJ; Pollack A; Harris EE; Price RA; Verhey LJ; Roach M; Demanes DJ; Steinberg ML; Potters L; Wallner PE; Konski A
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):671-7. PubMed ID: 18262085
    [No Abstract]   [Full Text] [Related]  

  • 2. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
    Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
    Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
    Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal dose constraints for intensity modulated radiation therapy of the prostate.
    Swanson GP; Stathakis S
    Am J Clin Oncol; 2011 Apr; 34(2):188-95. PubMed ID: 20622649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Coote JH; Wylie JP; Cowan RA; Logue JP; Swindell R; Livsey JE
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1121-7. PubMed ID: 19131179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of intensity-modulated radiotherapy for prostate cancer using an empty bladder protocol.
    Tuan JK; Ha TC; Ong WS; Siow TR; Tham IW; Ng WL; Wang ML; Chua ET; Tan TW
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):e137-9. PubMed ID: 22795829
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy.
    Dörr W; Jaal J; Zips D
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():14-5. PubMed ID: 18166999
    [No Abstract]   [Full Text] [Related]  

  • 8. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.
    Fonteyne V; Villeirs G; Lumen N; De Meerleer G
    Radiother Oncol; 2009 Jul; 92(1):42-7. PubMed ID: 19356817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation using a hypofractionated, intensity-modulated radiation therapy boost for localized prostate cancer: preliminary results addressing concerns of high or low alpha/beta ratio.
    Shridhar R; Bolton S; Joiner MC; Forman JD
    Clin Genitourin Cancer; 2009 Oct; 7(3):E52-7. PubMed ID: 19815482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy.
    Bouchard M; Nadeau S; Gingras L; Raymond PE; Beaulieu F; Beaulieu L; Fortin A; Germain I
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1343-50. PubMed ID: 18294780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
    Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 gy to treat prostate cancer: in regard to Eade et al. (Int J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
    Cheung MR
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207039
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimated limits of IMRT dose escalation using varied planning target volume margins.
    Goulet CC; Herman MG; Hillman DW; Davis BJ
    Phys Med Biol; 2008 Jul; 53(14):3777-88. PubMed ID: 18574311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of intensity-modulated radiation therapy in anorectal cancer.
    Meyer JJ; Willett CG; Czito BG
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):585-93. PubMed ID: 18402525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.